ArticleJournal of the American Heart Association2016
Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population.
Article in Journal of the American Heart Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 138 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
138 citing papers in PubMed, 7 syntheses or guidelines pooled it, 272 citations in OpenAlex.
- Different antithrombotic strategies to prevent cardiovascular complications in Kawasaki patients: a systematic review and meta-analysis.BMC pediatrics · 2024Pooled it
- Longitudinal Cardiac Outcomes of Multisystem Inflammatory Syndrome in Children: A Systematic Review and Meta-Analysis.Pediatric cardiology · 2023Pooled it
- 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease.Arthritis & rheumatology (Hoboken, N.J.) · 2022Guideline
- 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease.Arthritis care & research · 2022Guideline
- American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2.Arthritis & rheumatology (Hoboken, N.J.) · 2021Guideline
- American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 1.Arthritis & rheumatology (Hoboken, N.J.) · 2020Guideline
- A Comprehensive Update on Kawasaki Disease Vasculitis and Myocarditis.Current rheumatology reports · 2020Pooled it
- Comparative effectiveness of two intravenous immunoglobulin products in children with Kawasaki disease, a nationwide cohort study.Scientific reports · 2023Trial
- Risk factors associated with progression and persistence of small- and medium-sized coronary artery aneurysms in Kawasaki disease: a prospective cohort study.European journal of pediatrics · 2020Trial
- Association of the Aggregate Index of Systemic Inflammation with coronary artery aneurysm in Kawasaki disease patients.Pediatric research · 2026Article
- Acute Coronary Syndrome Linked to Massive Coronary Artery Aneurysms as Late Complications of Kawasaki Disease: A Case Report.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2026Article
- Characteristics and Outcomes of Patients with Regression of Coronary Artery Aneurysms Caused by Kawasaki Disease.Pediatric cardiology · 2026Article
- Predicting coronary artery lesions in Kawasaki disease: a nomogram based on LASSO regression feature selection.BMC medical informatics and decision making · 2026Article
- Advance in the Kawasaki disease related coronary artery aneurysms: knowledge mapping, trends, and research frontiers.Journal of cardiothoracic surgery · 2026Review
- A predictive model for long-term coronary artery lesion risk in Kawasaki disease.Frontiers in pediatrics · 2026Article
- Nomogram for Predicting Regression of Persistent Coronary Artery Aneurysms in Kawasaki Disease: A Three-year Follow-up Cohort Study in Southwest China.Journal of inflammation research · 2026Article
- Genetic liability to childhood Kawasaki disease and adult cardiovascular outcomes.Frontiers in cardiovascular medicine · 2026Article
- Giant coronary aneurysms in children with Kawasaki disease and major cardiac complications and dynamic follow-up.World journal of clinical pediatrics · 2025Article
- Midterm cardiovascular outcomes in children with MIS-C compared to Kawasaki disease: a multicenter prospective cohort study.Scientific reports · 2025Article
- Long-Term Outcomes of Coronary Artery Aneurysms in Children With Kawasaki Disease: A Systematic Review.Cureus · 2025Review
78 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe natural history of coronary artery aneurysms (CAA) after intravenous immunoglobulin (IVIG) treatment in the United States is not well described. We describe the natural history of CAA in US Kawasaki disease (KD) patients and identify factors associated with major adverse cardiac events (MACE) and CAA regression. METHODS AND
resultsWe evaluated all KD patients with CAA at 2 centers from 1979 to 2014. Factors associated with CAA regression, maximum CA z-score over time (zMax), and MACE were analyzed. We performed a matched analysis of treatment effect on likelihood of CAA regression. Of 2860 KD patients, 500 (17%) had CAA, including 90 with CAA z-score >10. Most (91%) received IVIG within 10 days of illness, 32% received >1 IVIG, and 27% received adjunctive anti-inflammatory medications. CAA regression occurred in 75%. Lack of CAA regression and higher CAA zMax were associated with earlier era, larger CAA z-score at diagnosis, and bilateral CAA in univariate and multivariable analyses. MACE occurred in 24 (5%) patients and was associated with higher CAA z-score at diagnosis and lack of IVIG treatment. In a subset of patients (n=132) matched by age at KD and baseline CAA z-score, those receiving IVIG plus adjunctive medication had a CAA regression rate of 91% compared with 68% for the 3 other groups (IVIG alone, IVIG ≥2 doses, or IVIG ≥2 doses plus adjunctive medication).
conclusionsCAA regression occurred in 75% of patients. CAA z-score at diagnosis was highly predictive of outcomes, which may be improved by early IVIG treatment and adjunctive therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.